Information Provided By:
Fly News Breaks for January 19, 2017
PTLA
Jan 19, 2017 | 16:10 EDT
Oppenheimer analyst Jay Olson started Portola Pharmaceuticals with a Perform rating and $28 price target. The analyst, while "optimistic" about Portola's two differentiated drugs for blood-related conditions, wants to wait for more clarity before recommending the shares given the company's "history of turmoil."
News For PTLA From the Last 2 Days
There are no results for your query PTLA